Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

BACKGROUND: Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering FcγRIII on natural kil...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Beano, Alessandra, Signorino, Elena, Evangelista, Andrea, Brusa, Davide, Mistrangelo, Marinella, Polimeni, Maria Antonia, Spadi, Rosella, Donadio, Michela, Ciuffreda, Libero, Matera, Lina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2008
Matèries:
Commentary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2415031/
https://ncbi.nlm.nih.gov/pubmed/18485193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-6-25
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars